Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

ATLANTA, Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN^® usage in Europe and the U.S. will be presented during the 18th European Society of Retina Specialists Congress (EURETINA), September 20-23, 2018, in Vienna, Austria. There will also be 15 electronic poster presentations highlighting the real-world data available throughout the meeting for review by EURETINA attendees.

On Friday, September 21, Alimera will sponsor a symposium as part of the EuroTimes Satellite Education Program. The lunchtime event entitled "CONTINUOUS MICRODOSING with ILUVIEN: Optimizing the Treatment of Persistent or Recurrent DME," will be moderated by Francesco Bandello from University Vita-Salute, Ospedale San Raffaele of Milan.

Panel participants include: Manuel Falcao from University of Porto, Porto, Portugal; Javier Zarranz-Ventura from Institut Clínic d´Oftalmologia at Hospital Clínic, Barcelona, Spain; and Albert Augustin, from Karlsruhe Klinikum, Karlsruhe, Germany.

The scheduled times and titles of the nine speaker presentations are as follows (all times local Vienna time):

Thursday, September 20

• A. Augustin, GERMANY
  The first report comparing the 3-year outcomes of ILUVIEN (fluocinolone acetonide) in vitrectomised and non-vitrectomised eyes in patients with DME – results from the RETRO-IDEAL study, 9:54 a.m.

• C. Pavesio, UK
  The first European presentation of the safety and efficacy outcomes with the 0.18 mg fluocinolone acetonide implant (FAc) for the treatment of non-infectious posterior segment uveitis (NIU-PS) - 12 month interim analyses from an ongoing 36 month trial, 11:30 a.m.

• R. Khoramnia, GERMANY 
  Injectable 0.19 mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema, 11:36 a.m.

Friday, September 21

• U. Chakravarthy, UK 
  Does the duration of chronic diabetic oedema influence the effectiveness and safety outcomes achieved in patients treated with ILUVIEN (fluocinolone acetonide)? Clinical insights from the ILUVIEN registry safety study, 3:18 p.m.

• C. Bailey, UK
  3-year results of a UK multi-centre audit of electronic medical records assessing real-world effectiveness and safety of ILUVIEN 190 micrograms intravitreal implant, 3:54 p.m.

• J. Zarranz-Ventura, SPAIN 
  Assessing the effectiveness of fluocinolone acetonide (0.2 µG/D FAc) and dexamethasone (DEX 700 µG) steroid implants in phase III pivotal trials using the area under the curve (AUC) method: The CONSTANT analysis, 4:36 p.m.

Sunday, September 23

• S. Vaz-Perrera, PORTUGAL  
  The outcomes of switching from a short-term to long-term intravitreal corticosteroids implant therapy in patients with diabetic macular edema (DME), 9:06 a.m.

• A. Eaton, U.S.A.  
  Realworld outcomes in the US following the use of the fluocinolone acetonide (FAc) 0.19 mg (ILUVIEN) implant in patients with diabetic macular edema: The results from the USER study, 10:42 a.m.

• A. Kotagiri, UK  
  Malposition of fluocinolone acetonide implants in patients with diabetic macular oedema: A possible cause of reduced efficacy, 10:54 a.m.

About ILUVIEN

U.S. website www.ILUVIEN.com

ILUVIEN'S U.S. Indication

ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months.

ILUVIEN'S E.U. Indication

ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.

About Diabetic Macular Edema (DME)

DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera Sciences (NASDAQ:ALIM), founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product portfolio. For more information, please visit www.alimerasciences.com.

SOURCE Alimera Sciences, Inc.

Related Links

www.alimerasciences.com